Zenagamtide + Tirzepatide for Obesity

This trial tests how well the drug zenagamtide works for individuals who are overweight or have obesity and are already using tirzepatide. The goal is to determine the best dose of zenagamtide to switch to after tirzepatide. All participants will receive both drugs. It suits those who have maintained a stable dose of tirzepatide for at least four weeks, and some may also have type 2 diabetes managed with specific oral medications. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new treatment.

Research has shown that tirzepatide is generally safe for most people. In studies, it helped many people lose weight and was usually well-tolerated. Most side effects were mild and mainly affected the stomach, such as nausea or diarrhea.

Detailed safety information for zenagamtide is not yet available. The trial is in the early stages, so researchers are still learning about its safety in humans. This phase is crucial for identifying any unexpected issues when people first use the treatment.

Researchers are excited about tirzepatide and zenagamtide for obesity because they offer a fresh approach compared to existing treatments like lifestyle changes, medications such as orlistat, and surgical options like bariatric surgery. Tirzepatide is unique because it is a dual agonist, meaning it targets two different hormones that regulate insulin and appetite, potentially enhancing weight loss. Zenagamtide, on the other hand, offers a novel mechanism by acting as a gut hormone analog, which may help improve metabolism and reduce food intake. Together, these treatments could offer a more effective and convenient option for managing obesity, as they are administered via once-weekly injections, simplifying the treatment regimen.

Research has shown that tirzepatide effectively aids weight loss in people with obesity. Studies found that participants using tirzepatide lost over 22% of their body weight on average and experienced significant improvements in body shape. Approximately 78% of participants lost at least 5% of their weight, with many losing even more. Although newer and less researched, zenagamtide is believed to help by reducing appetite and boosting metabolism. In this trial, participants will receive both tirzepatide and zenagamtide, aiming to provide a robust combined approach to managing obesity.⁶⁷⁸⁹¹⁰